A case report of advanced pancreatic cancer patient demonstrating remarkable efficacy with liposomal irinotecan after failure of multiple-line therapies

Read full text Summarise with VIRAT
Authors: Siyu Yu, Hong Zhu
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pancreatic cancer remains one of the most aggressive malignancies with an exceptionally poor prognosis. We herein report a case of a 53-year-old male diagnosed with pancreatic tail adenocarcinoma accompanied by extensive hepatic metastases. Despite receiving standard first-line FOLFIRINOX chemotherapy, the patient demonstrated progressive disease accompanied by severe anemia and persistently elevated tumor markers. Subsequent second-line therapy combining gemcitabine/nab-paclitaxel (GA regimen) failed to achieve disease control. Third-line treatment employing lenvatinib plus sintilimab (an anti-PD-1 immune checkpoint inhibitor) similarly resulted in disease progression (PD, Progressive Disease). Remarkably, after transitioning to Nal-IRI-based therapy, the patient achieved a durable partial response (PR) sustained for 10 months (Progression-Free Survival, PFS = 10 months) with favorable tolerability. In this challenging case of irinotican-resistant pancreatic cancer involving both hepatic and multiple osseous metastases, Nal-IRI demonstrated exceptional clinical activity as a later line therapeutic intervention, maintaining disease control for nearly one year with manageable toxicity. These observations suggest that Nal-IRI may represent a viable later line treatment strategy for advanced irinotican-resistant pancreatic cancer, warranting further investigation through prospective clinical trials.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Pancreatitis Pathology and Treatment Cancer Treatment and Pharmacology

Publication details

Journal / source
Frontiers in Oncology
Volume
16
Pages
1715778–1715778
Publication date
25 March 2026
Language
EN